The neuropeptide Y system: Pathophysiological and therapeutic implications in obesity and cancer (Q37857947)

1

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Kinetic study of neuropeptide Y (NPY) proteolysis in blood and identification of NPY3-35: a new peptide generated by plasma kallikrein

28 November 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Peptide YY(3-36) inhibits both anorexigenic proopiomelanocortin and orexigenic neuropeptide Y neurons: implications for hypothalamic regulation of energy homeostasis.

28 November 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

PYY[3-36] administration decreases the respiratory quotient and reduces adiposity in diet-induced obese mice

28 November 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Effects of peptide YY[3-36] on short-term food intake in mice are not affected by prevailing plasma ghrelin levels

28 November 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Lack of effect of pancreatic polypeptide in the rate of gastric emptying and gut hormone release during breakfast

28 November 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Role of leptin in the neuroendocrine response to fasting

28 November 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Hypothalamic neuropeptide Y and its gene expression: relation to light/dark cycle and circulating corticosterone

28 November 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Specific inhibition of endogenous neuropeptide Y synthesis in arcuate nucleus by antisense oligonucleotides suppresses feeding behavior and insulin secretion

28 November 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y in the arcuate nucleus is modulated by alterations in glucose utilization

28 November 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Gastrointestinal hormones in anorexia nervosa

28 November 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y and its flanking peptide in human endocrine tumors and plasma

28 November 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Conditional deletion of hypothalamic Y2 receptors reverts gonadectomy-induced bone loss in adult mice

28 November 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty

28 November 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist

28 November 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin

28 November 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Mouse pancreatic polypeptide modulates food intake, while not influencing anxiety in mice

28 November 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Characterization of the effects of pancreatic polypeptide in the regulation of energy balance

28 November 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

An arcuato-paraventricular and -dorsomedial hypothalamic neuropeptide Y-containing system which lacks noradrenaline in the rat.

28 November 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y family of hormones: receptor subtypes and antagonists

28 November 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar affinity

28 November 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Structure-activity studies including a Psi(CH(2)-NH) scan of peptide YY (PYY) active site, PYY(22-36), for interaction with rat intestinal PYY receptors: development of analogues with potent in vivo activity in the intestine

28 November 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Novel role of Y1 receptors in the coordinated regulation of bone and energy homeostasis

28 November 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Hypothalamic Y2 receptors regulate bone formation

28 November 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Peptide YY(1-36) and peptide YY(3-36): Part II. Changes after gastrointestinal surgery and bariatric surgery

28 November 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Effects of albumin-conjugated PYY on food intake: the respective roles of the circumventricular organs and vagus nerve

28 November 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Plasma orexin A, orexin B, leptin, neuropeptide Y (NPY) and insulin in obese women

28 November 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Cloning and Functional Expression of a Human Y4 Subtype Receptor for Pancreatic Polypeptide, Neuropeptide Y, and Peptide YY

28 November 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Inhibition of food intake in obese subjects by peptide YY3-36

28 November 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Gut hormone PYY(3-36) physiologically inhibits food intake

28 November 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Critical role for peptide YY in protein-mediated satiation and body-weight regulation

28 November 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Pancreatic polypeptide reduces appetite and food intake in humans

28 November 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Hypothalamic neuropeptide Y messenger ribonucleic acid levels in pre-obese and genetically obese (fa/fa) rats; potential regulation thereof by corticotropin-releasing factor

28 November 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes.

28 November 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Pancreatic polypeptide infusions reduce food intake in Prader-Willi syndrome

28 November 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Adaptive activation of thyroid hormone and energy expenditure

28 November 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Effects of intracerebroventricular injection of neuropeptide Y on energy metabolism

28 November 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y in hypothalamic paraventricular nucleus: a center coordinating energy metabolism

28 November 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Discovery and optimization of a series of carbazole ureas as NPY5 antagonists for the treatment of obesity

28 November 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Y-receptor subtypes--how many more?

28 November 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Low serum PYY is linked to insulin resistance in first-degree relatives of subjects with type 2 diabetes

28 November 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

PYY transgenic mice are protected against diet-induced and genetic obesity

28 November 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity

28 November 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Characterization of N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-[1-(2-cyclopentyl-ethyl)-piperidin-4yl]acrylamide (JNJ-5207787), a small molecule antagonist of the neuropeptide Y Y2 receptor

28 November 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Sympathetic innervation of white adipose tissue and its regulation of fat cell number.

28 November 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptides, including neuropeptide Y and melanocortins, mediate lipolysis in murine adipocytes

28 November 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Entry of peroxidase into neurons of the central and peripheral nervous systems from extracerebral and cerebral blood

28 November 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y innervation and neuropeptide-Y-Y1-receptor-expressing neurons in the paraventricular hypothalamic nucleus of the mouse

28 November 2024

51

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Overexpression of carnitine palmitoyltransferase-1 in skeletal muscle is sufficient to enhance fatty acid oxidation and improve high-fat diet-induced insulin resistance

28 November 2024

52

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Increased insulin concentrations and glucose storage in neuropeptide Y Y1 receptor-deficient mice

28 November 2024

53

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

The first selective agonist for the neuropeptide YY5 receptor increases food intake in rats

28 November 2024

54

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults

28 November 2024

55

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y administered chronically into the lateral ventricle profoundly inhibits both the gonadotropic and the somatotropic axis in intact adult female rats

28 November 2024

57

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY(3-36).

28 November 2024

59

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Regulation of hypothalamic neuropeptide-Y neurons by growth hormone in the rat.

28 November 2024

60

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Antagonism of NPY-induced feeding by pretreatment with cyclic AMP response element binding protein antisense oligonucleotide

28 November 2024

61

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Alteration of NPY and Y1 receptor in dorsomedial and ventromedial areas of hypothalamus in anorectic tumor-bearing rats

28 November 2024

62

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Daily, intermittent intravenous infusion of peptide YY(3-36) reduces daily food intake and adiposity in rats

28 November 2024

63

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Whole-body insulin resistance in the absence of obesity in FVB mice with overexpression of Dgat1 in adipose tissue

28 November 2024

64

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats

28 November 2024

65

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Peptide YY is critical for acylethanolamine receptor Gpr119-induced activation of gastrointestinal mucosal responses

28 November 2024

66

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor

28 November 2024

67

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Dissociated feeding and hypothermic effects of neuropeptide Y in the paraventricular and perifornical hypothalamus

28 November 2024

68

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Metabolic consequences of hyperinsulinaemia imposed on normal rats on glucose handling by white adipose tissue, muscles and liver

28 November 2024

69

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Food intake inhibition and reduction in body weight gain in lean and obese rodents treated with GW438014A, a potent and selective NPY-Y5 receptor antagonist

28 November 2024

70

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

High-affinity neuropeptide Y receptor antagonists

28 November 2024

71

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Effect of peptide YY3-36 on food intake in humans

28 November 2024

72

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Reduced food intake in response to CGP 71683A may be due to mechanisms other than NPY Y5 receptor blockade

28 November 2024

73

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

A potent and selective NPY Y5 antagonist reduces food intake but not through blockade of the NPY Y5 receptor

28 November 2024

74

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Production, characterization, and expression of neuropeptide Y by human pheochromocytoma

28 November 2024

75

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Human neuropeptide Y signal peptide gain-of-function polymorphism is associated with increased body mass index: possible mode of function

28 November 2024

76

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist

28 November 2024

77

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Adaptive changes in energy expenditure during refeeding following low-calorie intake: evidence for a specific metabolic component favoring fat storage.

28 November 2024

79

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y and neuropeptide Y receptor subtypes in brain and peripheral tissues

28 November 2024

80

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Evidence for the existence of an additional class of neuropeptide Y receptor sites in rat brain.

28 November 2024

81

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide-Y stimulation of insulin secretion is mediated via the nucleus tractus solitarius

28 November 2024

82

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Expression of a novel neuropeptide Y receptor subtype involved in food intake: an in situ hybridization study of Y5 mRNA distribution in rat brain

28 November 2024

83

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Evidence from knockout mice for distinct implications of neuropeptide-Y Y2 and Y4 receptors in the circadian control of locomotion, exploration, water and food intake

28 November 2024

84

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers

28 November 2024

85

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Distribution of pancreatic polypeptide and peptide YY

28 November 2024

86

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Deletion of neuropeptide Y (NPY) 2 receptor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing

28 November 2024

87

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

The central melanocortin system and the integration of short- and long-term regulators of energy homeostasis

28 November 2024

88

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Diet-induced obesity causes severe but reversible leptin resistance in arcuate melanocortin neurons

28 November 2024

90

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults

28 November 2024

91

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss

28 November 2024

92

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Modulation of central leptin sensitivity and energy balance in a rat model of diet-induced obesity

28 November 2024

93

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y1 and Y5 receptors mediate the effects of neuropeptide Y on the hypothalamic-pituitary-thyroid axis

28 November 2024

95

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Distribution of NPY receptors in the hypothalamus

28 November 2024

96

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans.

28 November 2024

97

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

[Leu31, Pro34]neuropeptide Y: a specific Y1 receptor agonist

28 November 2024

98

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults

28 November 2024

99

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Selective activation of central NPY Y1 vs. Y5 receptor elicits hyperinsulinemia via distinct mechanisms

28 November 2024

100

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

The neuropeptide Y Y1 receptor selective radioligand, [125I][Leu31,Pro34]peptide YY, is also a high affinity radioligand for human pancreatic polypeptide 1 receptors

28 November 2024

101

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

A receptor subtype involved in neuropeptide-Y-induced food intake

28 November 2024

102

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Expression Cloning and Pharmacological Characterization of a Human Hippocampal Neuropeptide Y/Peptide YY Y2 Receptor Subtype

28 November 2024

103

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Synthesis and evaluation of 5,5-diphenylimidazolones as potent human neuropeptide Y5 receptor antagonists

28 November 2024

104

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Energy metabolism and obesity

28 November 2024

105

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Identification and distribution of mRNA encoding the Y1, Y2, Y4, and Y5 receptors for peptides of the PP-fold family in the rat intestine and colon

28 November 2024

106

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Peptide YY inhibits growth of human breast cancer in vitro and in vivo

28 November 2024

107

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Characterization of a selective antagonist of neuropeptide Y at the Y2 receptor. Synthesis and pharmacological evaluation of a Y2 antagonist

28 November 2024

108

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Physiological evidence for the involvement of peptide YY in the regulation of energy homeostasis in humans

28 November 2024

109

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Further studies on the effects of central administration of neuropeptide Y on neuroendocrine function in the male rat: relationship to hypothalamic catecholamines

28 November 2024

110

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Autonomic control of pancreatic polypeptide and glucagon secretion during neuroglucopenia and hypoglycemia in mice

28 November 2024

111

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Characterisation of the neuropeptide Y receptor that mediates feeding in the rat: a role for the Y5 receptor?

28 November 2024

112

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Peptide YY augments gross inhibition by vitamin E succinate of human pancreatic cancer cell growth

28 November 2024

113

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Energy metabolic profile of mice after chronic activation of central NPY Y1, Y2, or Y5 receptors

28 November 2024

114

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y and energy homeostasis: insights from Y receptor knockout models

28 November 2024

115

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Overlapping gene structure of the human neuropeptide Y receptor subtypes Y1 and Y5 suggests coordinate transcriptional regulation

28 November 2024

117

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Cloned human neuropeptide Y receptor couples to two different second messenger systems

28 November 2024

118

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Feeding behavior and gene expression of appetite-related neuropeptides in mice lacking for neuropeptide Y Y5 receptor subclass

28 November 2024

119

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Potent and Selective 1,2,3-Trisubstituted Indole NPY Y-1 Antagonists

28 November 2024

120

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Pancreatic polypeptide is increased in patients with advanced malignant disease

28 November 2024

121

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Diurnal profile of pancreatic polypeptide, pancreatic glucagon, gut glucagon and insulin in human morbid obesity

28 November 2024

123

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Gene duplication of the human peptide YY gene (PYY) generated the pancreatic polypeptide gene (PPY) on chromosome 17q21.1

28 November 2024

124

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y is neuroproliferative for post-natal hippocampal precursor cells

28 November 2024

125

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

The level of NPY receptor mRNA expression in diet-induced obese and resistant mice

28 November 2024

126

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Gut peptides and the regulation of appetite.

28 November 2024

127

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Activation of the NPY Y5 receptor regulates both feeding and energy expenditure

28 November 2024

128

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Plasma and cerebroventricular fluid levels of pancreatic polypeptide in the dog: effects of feeding, insulin-induced hypoglycemia, and physical exercise

28 November 2024

129

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice

28 November 2024

130

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Blockade of body weight gain and plasma corticosterone levels in Zucker fatty rats using an orally active neuropeptide Y Y1 antagonist

28 November 2024

131

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y, leptin, and cholecystokinin 8 in patients with advanced cancer and anorexia: a North Central Cancer Treatment Group exploratory investigation

28 November 2024

133

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Low-dose pancreatic polypeptide inhibits food intake in man

28 November 2024

134

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

28 November 2024

Q28293680

135

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Altered intracellular processing and release of neuropeptide Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans.

28 November 2024

136

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y secretion increases in the paraventricular nucleus in association with increased appetite for food

28 November 2024

137

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Central effect of ghrelin, an endogenous growth hormone secretagogue, on hypothalamic peptide gene expression

28 November 2024

138

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

A typical Y1 receptor regulates feeding behaviors: effects of a potent and selective Y1 antagonist, J-115814.

28 November 2024

139

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

L-152,804: orally active and selective neuropeptide Y Y5 receptor antagonist

28 November 2024

141

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

The novel neuropeptide Y Y(1) receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability

28 November 2024

142

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice

28 November 2024

143

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Effect of Y1 receptor deficiency on motor activity, exploration, and anxiety

28 November 2024

144

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels

28 November 2024

145

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y Y(5) receptor antagonist CGP71683A: the effects on food intake and anxiety-related behavior in the rat.

28 November 2024

146

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Roles of pancreatic polypeptide in regulation of food intake

28 November 2024

147

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Effect of a selective neuropeptide Y Y(2) receptor antagonist, BIIE0246 on neuropeptide Y release

28 November 2024

148

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y: Y1 and Y2 affinities of the complete series of analogues with single D-residue substitutions

28 November 2024

149

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y in neural crest-derived tumors: effect on growth and vascularization

28 November 2024

150

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y (NPY) in neuroblastoma: effect on growth and vascularization

28 November 2024

151

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors

28 November 2024

152

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y as a marker in pediatric neuroblastoma

28 November 2024

153

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Plasma neuropeptide Y in healthy children: influence of age, anaesthesia and the establishment of an age-adjusted reference interval.

28 November 2024

154

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

A role for pancreatic polypeptide in feeding and body weight regulation

28 November 2024

155

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

High expression of neuropeptide Y1 receptors in ewing sarcoma tumors

28 November 2024

156

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Pancreatic polypeptide is involved in the regulation of body weight in pima Indian male subjects.

28 November 2024

157

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Centrally truncated and stabilized porcine neuropeptide Y analogs: design, synthesis, and mouse brain receptor binding

28 November 2024

159

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Inducible gene targeting in mice

28 November 2024

160

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome

28 November 2024

161

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Obesity and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor-deficient mice

28 November 2024

162

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Evolution of neuropeptide Y, peptide YY and pancreatic polypeptide

28 November 2024

163

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Low plasma levels of pancreatic polypeptide in obesity

28 November 2024

165

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Common neuropeptide Y2 receptor gene variant is protective against obesity among Swedish men.

28 November 2024

166

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Attenuated peptide YY release in obese subjects is associated with reduced satiety.

28 November 2024

167

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Supraphysiological doses of intravenous PYY 3-36 cause nausea, but no additional reduction in food intake

28 November 2024

168

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Critical role for Y1 receptors in mesenchymal progenitor cell differentiation and osteoblast activity

28 November 2024

169

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Synergistic attenuation of obesity by Y2- and Y4-receptor double knockout in ob/ob mice

28 November 2024

170

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Osteoblast specific Y1 receptor deletion enhances bone mass

28 November 2024

171

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Changes in Energy Expenditure Resulting from Altered Body Weight

28 November 2024

172

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y, epinephrine and norepinephrine in the paraventricular nucleus: stimulation of feeding and the release of corticosterone, vasopressin and glucose

28 November 2024

173

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Role of nonexercise activity thermogenesis in resistance to fat gain in humans.

28 November 2024

174

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Regulatory effects of Y4 receptor agonist (BVD-74D) on food intake

28 November 2024

175

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Functional expression of neuropeptide Y receptors in human neuroblastoma cells

28 November 2024

176

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Plasma cholecystokinin and pancreatic polypeptide secretion in response to bombesin, meal ingestion and modified sham feeding in lean and obese persons

28 November 2024

177

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Compensatory changes in [125I]-PYY binding in Y receptor knockout mice suggest the potential existence of further Y receptor(s)

28 November 2024

178

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Fasting inhibits the growth and reproductive axes via distinct Y2 and Y4 receptor-mediated pathways

28 November 2024

179

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Combined deletion of Y1, Y2, and Y4 receptors prevents hypothalamic neuropeptide Y overexpression-induced hyperinsulinemia despite persistence of hyperphagia and obesity

28 November 2024

180

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Critical role of arcuate Y4 receptors and the melanocortin system in pancreatic polypeptide-induced reduction in food intake in mice

28 November 2024

181

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Leptin receptor, NPY, POMC mRNA expression in the diet-induced obese mouse brain.

28 November 2024

182

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Human pancreatic cancer growth is inhibited by peptide YY and BIM-43004-1.

28 November 2024

183

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Adjuvant hormonal treatment with peptide YY or its analog decreases human pancreatic carcinoma growth

28 November 2024

184

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

The effects of pancreatic polypeptide on locomotor activity and food intake in mice

28 November 2024

185

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Y2 receptors decrease human pancreatic cancer growth and intracellular cyclic adenosine monophosphate levels

28 November 2024

186

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy

28 November 2024

187

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance

28 November 2024

188

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Greater bone formation of Y2 knockout mice is associated with increased osteoprogenitor numbers and altered Y1 receptor expression

28 November 2024

189

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Cloning of a human receptor of the NPY receptor family with high affinity for pancreatic polypeptide and peptide YY

28 November 2024

190

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis

28 November 2024

192

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Variations in peptide YY and Y2 receptor genes are associated with severe obesity in Pima Indian men.

28 November 2024

193

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Vasoactive intestinal polypeptide (VIP) and neuropeptide tyrosine (NPY) in prostate carcinoma

28 November 2024

194

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Enhanced metabolic efficiency contributes to weight regain after weight loss in obesity-prone rats

28 November 2024

195

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Expression of neuropeptide Y receptors in human prostate cancer cells

28 November 2024

196

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Cholinergic regulation of ghrelin and peptide YY release may be impaired in obesity

28 November 2024

197

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Normalization of hypothalamic serotonin (5-HT 1B) receptor and NPY in cancer anorexia after tumor resection: an immunocytochemical study

28 November 2024

198

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Decreased NPY innervation of the hypothalamic nuclei in rats with cancer anorexia.

28 November 2024

199

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Pancreatic polypeptide: a possible role in the regulation of food intake in the mouse. Hypothesis

28 November 2024

200

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Influence of TASP-V, a novel neuropeptide Y (NPY) Y2 agonist, on nasal and bronchial responses evoked by histamine in anaesthetized pigs and in humans

28 November 2024

201

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Successful validation of the palliative prognostic score in terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care.

28 November 2024

202

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Peptide YY Y1 receptor activates mitogen-activated protein kinase and proliferation in gut epithelial cells via the epidermal growth factor receptor

28 November 2024

203

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Localization of insulin receptor mRNA in rat brain by in situ hybridization

28 November 2024

204

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Role of the Y5 neuropeptide Y receptor in feeding and obesity

28 November 2024

205

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Pre-obese and obese agouti mice are sensitive to the anorectic effects of peptide YY(3-36) but resistant to ghrelin

28 November 2024

206

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine

28 November 2024

207

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

A pair-feeding study reveals that a Y5 antagonist causes weight loss in diet-induced obese mice by modulating food intake and energy expenditure

28 November 2024

208

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Characterization of Neuropeptide Y (NPY) Y5 Receptor-Mediated Obesity in Mice: Chronic Intracerebroventricular Infusion ofd-Trp34NPY

28 November 2024

209

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Synergistic interaction between neuropeptide Y1 and Y5 receptor pathways in regulation of energy homeostasis.

28 November 2024

210

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations

28 November 2024

211

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

2-36[K4,RYYSA(19-23)]PP a novel Y5-receptor preferring ligand with strong stimulatory effect on food intake.

28 November 2024

212

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Observations on the affinity for carnitine, and malonyl-CoA sensitivity, of carnitine palmitoyltransferase I in animal and human tissues. Demonstration of the presence of malonyl-CoA in non-hepatic tissues of the rat

28 November 2024

213

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Effect of pancreatic polypeptide on rat dorsal vagal complex neurons

28 November 2024

214

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Pancreatic polypeptide stimulates gastric acid secretion through a vagal mechanism in rats

28 November 2024

215

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Pancreatic polypeptide stimulates gastric motility through a vagal-dependent mechanism in rats

28 November 2024

216

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Tumor anorexia: effects on neuropeptide Y and monoamines in paraventricular nucleus

28 November 2024

217

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

28 November 2024

218

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors

28 November 2024

219

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Plasma insulin, cholecystokinin, galanin, neuropeptide Y and leptin levels in obese women with and without type 2 diabetes mellitus

28 November 2024

220

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

A common single nucleotide polymorphism alters the synthesis and secretion of neuropeptide Y

28 November 2024

221

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y: direct and indirect action on insulin secretion in the rat.

28 November 2024

222

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Inhibition of glucose stimulated insulin secretion by neuropeptide Y is mediated via the Y1 receptor and inhibition of adenylyl cyclase in RIN 5AH rat insulinoma cells

28 November 2024

223

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y induces migration, proliferation, and tube formation of endothelial cells bimodally via Y1, Y2, and Y5 receptors

28 November 2024

224

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Pharmacological characterization of the cloned neuropeptide Y y(6) receptor

28 November 2024

225

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Identification of potent and selective neuropeptide Y Y(1) receptor agonists with orexigenic activity in vivo

28 November 2024

226

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Activation of extracellular signal regulated protein kinase by neuropeptide Y and pancreatic polypeptide in CHO cells expressing the NPY Y(1), Y(2), Y(4) and Y(5) receptor subtypes

28 November 2024

227

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

1,3-Disubstituted benzazepines as novel, potent, selective neuropeptide Y Y1 receptor antagonists

28 November 2024

228

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

A role for ghrelin in the central regulation of feeding

28 November 2024

229

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Complementary and overlapping expression of Y1, Y2 and Y5 receptors in the developing and adult mouse nervous system.

28 November 2024

230

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor.

28 November 2024

231

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Attenuation of hypercholesterolemia and hyperglycemia in ob/ob mice by NPY Y2 receptor ablation

28 November 2024

232

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

No evidence of an additive inhibitory feeding effect following PP and PYY3−36 administration

28 November 2024

233

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Effects of intracerebroventricular administration of the NPY-Y1 receptor antagonist, 1229U91, on hyperphagic and glycemic responses to acute and chronic intermediate insulin-induced hypoglycemia in female rats.

28 November 2024

234

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Conservation of expression of neuropeptide Y5 receptor between human and rat hypothalamus and limbic regions suggests an integral role in central neuroendocrine control

28 November 2024

235

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Leu7Pro polymorphism in the neuropeptide Y (NPY) gene is associated with impaired glucose tolerance and type 2 diabetes in Swedish men.

28 November 2024

236

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Peptide YY (PYY)3-36 modulates thyrotropin secretion in rats

28 November 2024

237

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

A novel long-acting selective neuropeptide Y2 receptor polyethylene glycol-conjugated peptide agonist reduces food intake and body weight and improves glucose metabolism in rodents

28 November 2024

238

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Mechanical signals as anabolic agents in bone

28 November 2024

239

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Implication of neuropeptide-Y Y2 receptors in the effects of immune stress on emotional, locomotor and social behavior of mice

28 November 2024

240

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

GR231118 (1229U91) and other analogues of the C-terminus of neuropeptide Y are potent neuropeptide Y Y1 receptor antagonists and neuropeptide Y Y4 receptor agonists.

28 November 2024

241

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

[D-Trp(34)] neuropeptide Y is a potent and selective neuropeptide Y Y(5) receptor agonist with dramatic effects on food intake

28 November 2024

242

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Regional distribution of Y-receptor subtype mRNAs in rat brain

28 November 2024

243

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Localization of Y-receptor subtype mRNAs in rat brain by digoxigenin labeled in situ hybridization

28 November 2024

244

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status

28 November 2024

245

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Predictors of weight maintenance

28 November 2024

246

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor

28 November 2024

247

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Interdigestive cycling and post-prandial release of pancreatic polypeptide in severe obesity

28 November 2024

248

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Chronic administration of neuropeptide Y into the lateral ventricle inhibits both the pituitary-testicular axis and growth hormone and insulin-like growth factor I secretion in intact adult male rats

28 November 2024

249

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

A new palliative prognostic score: a first step for the staging of terminally ill cancer patients. Italian Multicenter and Study Group on Palliative Care.

28 November 2024

250

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Effects of PYY[3-36] in rodent models of diabetes and obesity

28 November 2024

251

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

The neuropeptide Y Y1 receptor regulates leptin-mediated control of energy homeostasis and reproductive functions

28 November 2024

252

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y and peptide YY stimulate the growth of exocrine pancreatic carcinoma cells

28 November 2024

253

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Chronic administration of neuropeptide Y into the lateral ventricle of C57BL/6J male mice produces an obesity syndrome including hyperphagia, hyperleptinemia, insulin resistance, and hypogonadism.

28 November 2024

254

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Multiple receptors for neuropeptide Y in the hippocampus: putative roles in seizures and cognition

28 November 2024

255

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Effects of different intermittent peptide YY (3-36) dosing strategies on food intake, body weight, and adiposity in diet-induced obese rats

28 November 2024

256

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Bariatric surgery, weight reduction, and cancer prevention

28 November 2024

257

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Peptide YY: a potential therapy for obesity

28 November 2024

258

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Y(1)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets

28 November 2024

259

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Effects of changes in body weight on carbohydrate metabolism, catecholamine excretion, and thyroid function

28 November 2024

261

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Peptide YY is a regulator of energy homeostasis in obese children before and after weight loss

28 November 2024

262

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226.

28 November 2024

263

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Activation of the Y1 receptor by neuropeptide Y regulates the growth of prostate cancer cells.

28 November 2024

264

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Role of neuropeptide Y and its receptors in the progression of endocrine-related cancer.

28 November 2024

265

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Synergistic effects of Y2 and Y4 receptors on adiposity and bone mass revealed in double knockout mice.

28 November 2024

266

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Y2Y4 Receptor Double Knockout Protects Against Obesity Due to a High-Fat Diet or Y1 Receptor Deficiency in Mice

28 November 2024

267

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Hypothalamic regulation of energy homeostasis

28 November 2024

268

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Adrenalectomy prevents the obesity syndrome produced by chronic central neuropeptide Y infusion in normal rats

28 November 2024

269

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Inhibitory effects of central neuropeptide Y on the somatotropic and gonadotropic axes in male rats are independent of adrenal hormones

28 November 2024

270

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Chronic central neuropeptide Y infusion in normal rats: status of the hypothalamo-pituitary-adrenal axis, and vagal mediation of hyperinsulinaemia

28 November 2024

271

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Important role of hypothalamic Y2 receptors in body weight regulation revealed in conditional knockout mice

28 November 2024

272

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Y2 receptor deletion attenuates the type 2 diabetic syndrome of ob/ob mice

28 November 2024

273

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Y4 receptor knockout rescues fertility in ob/ob mice.

28 November 2024

274

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Role of the arcuate nucleus of the hypothalamus in regulation of body weight during energy deficit

28 November 2024

275

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

A role for pancreatic polypeptide in the regulation of gastric emptying and short-term metabolic control

28 November 2024

276

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Energy homeostasis and gastrointestinal endocrine differentiation do not require the anorectic hormone peptide YY.

28 November 2024

277

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Vagal, cholinergic regulation of pancreatic polypeptide secretion

28 November 2024

278

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Inhibition of hypothalamic neuropeptide Y gene expression by insulin

28 November 2024

279

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Intravenous peptide YY3-36 and Y2 receptor antagonism in the rat: effects on feeding behaviour.

28 November 2024

280

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Effect of 2-mercaptoacetate and 2-deoxy-D-glucose administration on the expression of NPY, AGRP, POMC, MCH and hypocretin/orexin in the rat hypothalamus

28 November 2024

281

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Characterization of NPY receptors controlling lipolysis and leptin secretion in human adipocytes

28 November 2024

282

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

SR 120819A, an orally-active and selective neuropeptide Y Y1 receptor antagonist

28 November 2024

283

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y Y5 receptor promotes cell growth through extracellular signal-regulated kinase signaling and cyclic AMP inhibition in a human breast cancer cell line

28 November 2024

284

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y treatment and food deprivation increase cyclic AMP response element-binding in rat hypothalamus

28 November 2024

285

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

NPY neuron-specific Y2 receptors regulate adipose tissue and trabecular bone but not cortical bone homeostasis in mice

28 November 2024

286

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway.

28 November 2024

287

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Single nucleotide polymorphisms in the neuropeptide Y2 receptor (NPY2R) gene and association with severe obesity in French white subjects

28 November 2024

289

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Thermogenic mechanisms and their hormonal regulation

28 November 2024

290

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Pancreatic polypeptide (PP) responses to oral and intravenous glucose in man

28 November 2024

291

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males

28 November 2024

292

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Effects of PYY1–36 and PYY3–36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects

28 November 2024

293

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Peptide analogue studies of the hypothalamic neuropeptide Y receptor mediating pituitary adrenocorticotrophic hormone release

28 November 2024

294

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Effects of a selective neuropeptide Y Y2 receptor antagonist, BIIE0246, on Y2 receptors at peripheral neuroeffector junctions

28 November 2024

295

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Novel analogues of neuropeptide Y with a preference for the Y1-receptor

28 November 2024

296

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Central nervous system neuropeptide Y signaling modulates VLDL triglyceride secretion.

28 November 2024

297

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity

28 November 2024

298

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

The role of neuropeptide Y in the antiobesity action of the obese gene product

28 November 2024

299

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents

28 November 2024

300

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Thermoregulatory effect of intracerebral injections of neuropeptide Y in rats at different environmental temperatures

28 November 2024

301

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Increased plasma immunoreactive neuropeptide Y concentrations in phaeochromocytoma and chronic renal failure

28 November 2024

302

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice

28 November 2024

303

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Effects of pancreatic polypeptide, caerulein, and bombesin on satiety in obese mice

28 November 2024

304

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Effect of atropine and vagotomy on pancreatic polypeptide response to a meal in dogs

28 November 2024

305

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Protein meal-stimulated pancreatic polypeptide secretion in Prader-Willi syndrome of adults

28 November 2024

306

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Variants in the 5′ region of the neuropeptide Y receptor Y2 gene (NPY2R) are associated with obesity in 5,971 white subjects

28 November 2024

307

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Human pancreatic polypeptide: studies of fasting and postprandial plasma concentrations

28 November 2024

308

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Differential regulation of neuropeptide Y receptors in the brains of NPY knock-out mice

28 November 2024

309

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Selective antagonism of the NPY Y5 receptor does not have a major effect on feeding in rats

28 November 2024

310

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Excess Lipid Availability Increases Mitochondrial Fatty Acid Oxidative Capacity in Muscle

28 November 2024

311

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice

28 November 2024

312

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Potential regulators of feeding behavior In anorexia nervosa

28 November 2024

313

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Leu7Pro polymorphism of PreproNPY associated with an increased risk for type II diabetes in middle-aged subjects

28 November 2024

314

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY

28 November 2024

315

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y and peptide YY inhibit lipolysis in human and dog fat cells through a pertussis toxin-sensitive G protein

28 November 2024

316

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-fat diet

28 November 2024

317

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Chronic PYY3–36 treatment promotes fat oxidation and ameliorates insulin resistance in C57BL6 mice

28 November 2024

318

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

PYY(3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity

28 November 2024

319

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y (NPY) in the area of the hypothalamic paraventricular nucleus activates the pituitary-adrenocortical axis in the rat.

28 November 2024

321

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Evidence for different pre-and post-junctional receptors for neuropeptide Y and related peptides

28 November 2024

322

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Association analysis of the polymorphism T1128C in the signal peptide of neuropeptide Y in a Swedish hypertensive population

28 November 2024

323

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Evidence of a paracrine role of neuropeptide-Y in the regulation of insulin release from pancreatic islets of normal and dexamethasone-treated rats

28 November 2024

324

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Difference of NPY and its receptor gene expressions between obesity and obesity-resistant rats in response to high-fat diet

28 November 2024

325

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

The Y1 receptor for NPY: a key modulator of the adaptive immune system.

28 November 2024

326

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

NPY and receptors in immune and inflammatory diseases.

28 November 2024

327

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents

28 November 2024

328

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Co-localization of growth hormone secretagogue receptor and NPY mRNA in the arcuate nucleus of the rat

28 November 2024

330

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Plasma concentrations of regulatory peptides in obesity following modified sham feeding (MSF) and a liquid test meal

28 November 2024

331

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Y1-receptors regulate the expression of Y2-receptors in distinct mouse forebrain areas

28 November 2024

332

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Peptide YY regulates bone turnover in rodents.

28 November 2024

333

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

The pharmacology of neuropeptide Y (NPY) receptor-mediated feeding in rats characterizes better Y5 than Y1, but not Y2 or Y4 subtypes

28 November 2024

334

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Neuropeptide Y is produced in visceral adipose tissue and promotes proliferation of adipocyte precursor cells via the Y1 receptor

28 November 2024

335

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Obese reversal by a chronic energy restricted diet leaves an increased Arc NPY/AgRP, but no alteration in POMC/CART, mRNA expression in diet-induced obese mice.

28 November 2024

336

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Vitamin E and the Y4 agonist BA-129 decrease prostate cancer growth and production of vascular endothelial growth factor

28 November 2024

337

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity

28 November 2024

338

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Intracerebroventricular administration of neuropeptide Y to normal rats has divergent effects on glucose utilization by adipose tissue and skeletal muscle

28 November 2024

339

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Peripheral neuropeptide Y Y1 receptors regulate lipid oxidation and fat accretion

28 November 2024

340

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Structure-activity relationships of a series of 1-substituted-4-methylbenzimidazole neuropeptide Y-1 receptor antagonists

28 November 2024

342

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Pancreatic polypeptide responses to protein meal challenges in obese but otherwise normal children and obese children with Prader-Willi syndrome

28 November 2024

343

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011

Blunted pancreatic polypeptide responses in children with obesity of Prader-Willi syndrome

28 November 2024

344

1 reference

https://api.crossref.org/works/10.1016/J.PHARMTHERA.2011.03.011